{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:57:08Z","timestamp":1793822228097,"version":"4.6.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Peripheral T cell lymphoma (PTCL) is characterized by high heterogeneity, strong aggressiveness, and extremely poor prognosis. Ferroptosis, a novel form of programmed cell death, has been involved in tumor development and targeting ferroptosis holds great potential for tumor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Lentiviral transfection was performed to regulate gene expression, followed by Tandem mass tag (TMT)-mass spectrometry and RNA-sequencing. Tumor xenograft models were established for in vivo experiments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>High expression of prostaglandin D2 synthase (PTGDS) was closely associated with poor prognosis of PTCL patients. PTGDS knockdown and AT56 treatment significantly inhibited the progression of PTCL through regulating cell viability, proliferation, apoptosis, cell cycle and invasion in vitro and in vivo. We further revealed that targeting PTGDS promoted ferroptosis process and enhanced the sensitivity of PTCL cells to ferroptosis inducers Sorafenib in vitro and in vivo. Mechanically, PTGDS interacted with heme-degrading enzymes HMOX1, and targeting PTGDS increased the level of iron and induced ferroptosis in PTCL through promoting HMOX1-mediated heme catabolism and ferritin autophagy process. Through the construction of H25A mutation, the specific gene site of HMOX1 corresponding to its role was identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Taken together, our findings firstly identified that targeting PTGDS promotes the ferroptosis in PTCL through regulating HMOX1-mediated iron metabolism, and highlighted novel therapeutic strategies to improve the efficacy of ferroptosis-targeted therapy in PTCL patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-024-02919-w","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T16:46:04Z","timestamp":1734713164000},"page":"384-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting PTGDS Promotes ferroptosis in peripheral T cell lymphoma through regulating HMOX1-mediated iron metabolism"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-7065","authenticated-orcid":false,"given":"Shunfeng","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8051-1481","authenticated-orcid":false,"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2919_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: a cancer J Clin. 2023;73:17\u201348.","journal-title":"CA: a cancer J Clin"},{"key":"2919_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","volume":"13","author":"E Mulvey","year":"2020","unstructured":"Mulvey E, Ruan J. Biomarker-driven management strategies for peripheral T cell lymphoma. J Hematol Oncol. 2020;13:59.","journal-title":"J Hematol Oncol"},{"key":"2919_CR3","volume":"12","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenet. 2020;12:169.","journal-title":"Clin Epigenet"},{"key":"2919_CR4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107\u201325.","journal-title":"Cell Res"},{"key":"2919_CR5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2919_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41581-023-00689-x","volume":"19","author":"H Bayir","year":"2023","unstructured":"Bayir H, Dixon SJ, Tyurina YY, Kellum JA, Kagan VE. Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney. Nat Rev Nephrol. 2023;19:315\u201336.","journal-title":"Nat Rev Nephrol"},{"key":"2919_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89\u2013100.","journal-title":"Semin Cancer Biol"},{"key":"2919_CR8","volume":"166","author":"S Hu","year":"2023","unstructured":"Hu S, Chu Y, Zhou X, Wang X. Recent advances of ferroptosis in tumor: From biological function to clinical application. Biomed Pharmacother. 2023;166:115419.","journal-title":"Biomed Pharmacother"},{"key":"2919_CR9","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1039\/D3CS00001J","volume":"52","author":"N Kang","year":"2023","unstructured":"Kang N, Son S, Min S, Hong H, Kim C, An J, et al. Stimuli-responsive ferroptosis for cancer therapy. Chem Soc Rev. 2023;52:3955\u201372.","journal-title":"Chem Soc Rev"},{"key":"2919_CR10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"2919_CR11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41418-021-00880-2","volume":"29","author":"S Hu","year":"2022","unstructured":"Hu S, Ren S, Cai Y, Liu J, Han Y, Zhao Y, et al. Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-beta-catenin-STAT3 signaling. Cell Death Differ. 2022;29:642\u201356.","journal-title":"Cell Death Differ"},{"key":"2919_CR12","first-page":"3022","volume":"97","author":"LP He","year":"2017","unstructured":"He LP, Chen YF, Yang J. [Investigation on the role and mechanism of prostagland in D2 synthase in non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi. 2017;97:3022\u20137.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2919_CR13","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1158\/0008-5472.CAN-04-4439","volume":"65","author":"J Kim","year":"2005","unstructured":"Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, et al. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005;65:6189\u201398.","journal-title":"Cancer Res"},{"key":"2919_CR14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/stem.2821","volume":"36","author":"B Zhang","year":"2018","unstructured":"Zhang B, Bie Q, Wu P, Zhang J, You B, Shi H, et al. PGD2\/PTGDR2 Signaling Restricts the Self-Renewal and Tumorigenesis of Gastric Cancer. Stem Cells. 2018;36:990\u20131003.","journal-title":"Stem Cells"},{"key":"2919_CR15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41418-024-01322-5","volume":"31","author":"Y Deng","year":"2024","unstructured":"Deng Y, Lu L, Zhu D, Zhang H, Fu Y, Tan Y, et al. MafG\/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells. Cell Death Differ. 2024;31:1127\u201339.","journal-title":"Cell Death Differ"},{"key":"2919_CR16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/s41418-022-01008-w","volume":"29","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F, et al. Wnt\/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022;29:2190\u2013202.","journal-title":"Cell Death Differ"},{"key":"2919_CR17","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103255","volume":"75","author":"Z Feng","year":"2024","unstructured":"Feng Z, Meng F, Huo F, Zhu Y, Qin Y, Gui Y, et al. Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1\/TLR4\/STAT3 axis in M1 macrophages. Redox Biol. 2024;75:103255.","journal-title":"Redox Biol"},{"key":"2919_CR18","doi-asserted-by":"crossref","unstructured":"Di Y, Zhang X, Wen X, Qin J, Ye L, Wang Y, et al. MAPK Signaling-Mediated RFNG Phosphorylation and Nuclear Translocation Restrain Oxaliplatin-Induced Apoptosis and Ferroptosis. Adv Sci (Weinh). 2024;11:e2402795.","DOI":"10.1002\/advs.202402795"},{"key":"2919_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2022.06.247","volume":"189","author":"S Liu","year":"2022","unstructured":"Liu S, Shi J, Wang L, Huang Y, Zhao B, Ding H, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med. 2022;189:42\u201357.","journal-title":"Free Radic Biol Med"},{"key":"2919_CR20","doi-asserted-by":"crossref","unstructured":"Li W The 5(th) Edition of the World Health Organization Classification of Hematolymphoid Tumors. In: Li W, editor. Leukemia. Brisbane (AU)2022.","DOI":"10.36255\/exon-publications-leukemia-who-5th-edition-hematolymphoid-tumors"},{"key":"2919_CR21","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2002-06-1666","volume":"101","author":"J Peng","year":"2003","unstructured":"Peng J, Liu C, Liu D, Ren C, Li W, Wang Z, et al. Effects of B7-blocking agent and\/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood. 2003;101:2721\u20136.","journal-title":"Blood"},{"key":"2919_CR22","volume":"10","author":"C Zheng","year":"2023","unstructured":"Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, et al. Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. Adv Sci (Weinh). 2023;10:e2206798.","journal-title":"Adv Sci (Weinh)"},{"key":"2919_CR23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/15548627.2018.1476812","volume":"14","author":"N Meyer","year":"2018","unstructured":"Meyer N, Zielke S, Michaelis JB, Linder B, Warnsmann V, Rakel S, et al. AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy. 2018;14:1693\u2013709.","journal-title":"Autophagy"},{"key":"2919_CR24","doi-asserted-by":"crossref","unstructured":"Chiang SK, Chen SE, Chang LC. The Role of HO-1 and Its Crosstalk with Oxidative Stress in Cancer Cell Survival. Cells. 2021;10:2401.","DOI":"10.3390\/cells10092401"},{"key":"2919_CR25","doi-asserted-by":"crossref","first-page":"20621","DOI":"10.1074\/jbc.M607954200","volume":"282","author":"Q Lin","year":"2007","unstructured":"Lin Q, Weis S, Yang G, Weng YH, Helston R, Rish K, et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem. 2007;282:20621\u201333.","journal-title":"J Biol Chem"},{"key":"2919_CR26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00109-010-0613-6","volume":"88","author":"JD Belcher","year":"2010","unstructured":"Belcher JD, Vineyard JV, Bruzzone CM, Chen C, Beckman JD, Nguyen J, et al. Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. J Mol Med (Berl). 2010;88:665\u201375.","journal-title":"J Mol Med (Berl)"},{"key":"2919_CR27","volume":"12","author":"W Luo","year":"2021","unstructured":"Luo W, Li J, Li Z, Lin T, Zhang L, Yang W, et al. HO-1 nuclear accumulation and interaction with NPM1 protect against stress-induced endothelial senescence independent of its enzymatic activity. Cell Death Dis. 2021;12:738.","journal-title":"Cell Death Dis"},{"key":"2919_CR28","volume":"10","author":"K Hu","year":"2022","unstructured":"Hu K, Liu W, Gan Y, Huang Z. Transcriptome analysis of childhood Guillain-Barre syndrome associated with supportive care. Front Pediatr. 2022;10:1008996.","journal-title":"Front Pediatr"},{"key":"2919_CR29","first-page":"2254","volume":"41","author":"MR Alves","year":"2019","unstructured":"Alves MR, Do Amaral NS, Marchi FA, Silva FIB, Da Costa A, Carvalho KC, et al. Prostaglandin D2 expression is prognostic in high\u2011grade serous ovarian cancer. Oncol Rep. 2019;41:2254\u201364.","journal-title":"Oncol Rep"},{"key":"2919_CR30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.4993","volume":"244","author":"K Omori","year":"2018","unstructured":"Omori K, Morikawa T, Kunita A, Nakamura T, Aritake K, Urade Y, et al. Lipocalin-type prostaglandin D synthase-derived PGD(2) attenuates malignant properties of tumor endothelial cells. J Pathol. 2018;244:84\u201396.","journal-title":"J Pathol"},{"key":"2919_CR31","first-page":"3769","volume":"14","author":"Z Ren","year":"2022","unstructured":"Ren Z, Gao M, Jiang W. Prognostic role of NLGN2 and PTGDS in medulloblastoma based on gene expression omnibus. Am J Transl Res. 2022;14:3769\u201382.","journal-title":"Am J Transl Res"},{"key":"2919_CR32","volume":"21","author":"P Jiang","year":"2021","unstructured":"Jiang P, Cao Y, Gao F, Sun W, Liu J, Ma Z, et al. SNX10 and PTGDS are associated with the progression and prognosis of cervical squamous cell carcinoma. BMC cancer. 2021;21:694.","journal-title":"BMC cancer"},{"key":"2919_CR33","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.2147\/CMAR.S255753","volume":"12","author":"R Zou","year":"2020","unstructured":"Zou R, Zheng M, Tan M, Xu H, Luan N, Zhu L. Decreased PTGDS Expression Predicting Poor Survival of Endometrial Cancer by Integrating Weighted Gene Co-Expression Network Analysis and Immunohistochemical Validation. Cancer Manag Res. 2020;12:5057\u201375.","journal-title":"Cancer Manag Res"},{"key":"2919_CR34","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.7150\/jca.37637","volume":"11","author":"J Jiang","year":"2020","unstructured":"Jiang J, Pan W, Xu Y, Ni C, Xue D, Chen Z, et al. Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles. J Cancer. 2020;11:1568\u201383.","journal-title":"J Cancer"},{"key":"2919_CR35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/CAD.0000000000001111","volume":"32","author":"J Pan","year":"2021","unstructured":"Pan J, Zhang L, Huang J. Prostaglandin D2 synthase\/prostaglandin D2\/TWIST2 signaling inhibits breast cancer proliferation. Anticancer Drugs. 2021;32:1029\u201337.","journal-title":"Anticancer Drugs"},{"key":"2919_CR36","first-page":"71","volume":"23","author":"W Wang","year":"2022","unstructured":"Wang W, Yuan D, Jiang K, Li R, Qu H, Jiang FN, et al. Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis. Curr Cancer Drug Targets. 2022;23:71\u201386.","journal-title":"Curr Cancer Drug Targets"},{"key":"2919_CR37","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.1074\/jbc.M808593200","volume":"284","author":"D Irikura","year":"2009","unstructured":"Irikura D, Aritake K, Nagata N, Maruyama T, Shimamoto S, Urade Y. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. J Biol Chem. 2009;284:7623\u201330.","journal-title":"J Biol Chem"},{"key":"2919_CR38","doi-asserted-by":"crossref","unstructured":"Li C, Li J, Loreno EG, Miriyala S, Panchatcharam M, Sun H. Protective Effect of Low-Dose Alcohol Consumption against Post-Ischemic Neuronal Apoptosis: Role of L-PGDS. Int J Mol Sci. 2021;23:133.","DOI":"10.3390\/ijms23010133"},{"key":"2919_CR39","volume":"10","author":"S Wu","year":"2020","unstructured":"Wu S, Huang D, Su X, Yan H, Ma A, Li L, et al. The prostaglandin synthases, COX-2 and L-PGDS, mediate prostate hyperplasia induced by low-dose bisphenol A. Sci Rep. 2020;10:13108.","journal-title":"Sci Rep"},{"key":"2919_CR40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/1386207326666230731103112","volume":"27","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Wang F, Huang Y, Gao P, Wang N, Tian H, et al. PGD2\/PTGDR2 Signal Affects the Viability, Invasion, Apoptosis, and Stemness of Gastric Cancer Stem Cells and Prevents the Progression of Gastric Cancer. Comb Chem High Throughput Screen. 2024;27:933\u201346.","journal-title":"Comb Chem High Throughput Screen"},{"key":"2919_CR41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"2919_CR42","volume":"13","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Li T, Qin Q, Huang X, Wang Y. Ferroptosis in lymphoma: Emerging mechanisms and a novel therapeutic approach. Front Genet. 2022;13:1039951.","journal-title":"Front Genet"},{"key":"2919_CR43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175526","volume":"943","author":"SA Setiawan","year":"2023","unstructured":"Setiawan SA, Liu WZ, Weng PW, Lee CH, Yadav VK, Hardianti MS, et al. Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma. Eur J Pharm. 2023;943:175526.","journal-title":"Eur J Pharm"},{"key":"2919_CR44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbrc.2019.09.023","volume":"519","author":"N Wang","year":"2019","unstructured":"Wang N, Zeng GZ, Yin JL, Bian ZX. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt\u2019s Lymphoma. Biochem Biophys Res Commun. 2019;519:533\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2919_CR45","first-page":"498","volume":"13","author":"QT Huang","year":"2023","unstructured":"Huang QT, Hu QQ, Wen ZF, Li YL. Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma. Am J Cancer Res. 2023;13:498\u2013508.","journal-title":"Am J Cancer Res"},{"key":"2919_CR46","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","volume":"36","author":"Y Hong","year":"2022","unstructured":"Hong Y, Ren T, Wang X, Liu X, Fei Y, Meng S, et al. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia. 2022;36:2269\u201380.","journal-title":"Leukemia"},{"key":"2919_CR47","volume":"88","author":"Y Chen","year":"2021","unstructured":"Chen Y, Wang F, Wu P, Gong S, Gao J, Tao H, et al. Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling. Cell Signal. 2021;88:110167.","journal-title":"Cell Signal"},{"key":"2919_CR48","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1038\/onc.2014.166","volume":"34","author":"FF Hsu","year":"2015","unstructured":"Hsu FF, Yeh CT, Sun YJ, Chiang MT, Lan WM, Li FA, et al. Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity. Oncogene. 2015;34:2360\u201370.","journal-title":"Oncogene"},{"key":"2919_CR49","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1073\/pnas.82.23.7865","volume":"82","author":"S Shibahara","year":"1985","unstructured":"Shibahara S, Muller R, Taguchi H, Yoshida T. Cloning and expression of cDNA for rat heme oxygenase. Proc Natl Acad Sci USA. 1985;82:7865\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2919_CR50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41413-022-00198-w","volume":"10","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lin Y, Wang M, Yuan K, Wang Q, Mu P, et al. Targeting ferroptosis suppresses osteocyte glucolipotoxicity and alleviates diabetic osteoporosis. Bone Res. 2022;10:26.","journal-title":"Bone Res"},{"key":"2919_CR51","volume":"317","author":"JX Wang","year":"2023","unstructured":"Wang JX, Zhao Y, Chen MS, Zhang H, Cui JG, Li JL. Heme-oxygenase-1 as a target for phthalate-induced cardiomyocytes ferroptosis. Environ Pollut. 2023;317:120717.","journal-title":"Environ Pollut"},{"key":"2919_CR52","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1523\/JNEUROSCI.6469-11.2012","volume":"32","author":"W Song","year":"2012","unstructured":"Song W, Zukor H, Lin SH, Hascalovici J, Liberman A, Tavitian A, et al. Schizophrenia-like features in transgenic mice overexpressing human HO-1 in the astrocytic compartment. J Neurosci. 2012;32:10841\u201353.","journal-title":"J Neurosci"},{"key":"2919_CR53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/IJGM.S343046","volume":"15","author":"W Sun","year":"2022","unstructured":"Sun W, Yan J, Ma H, Wu J, Zhang Y. Autophagy-Dependent Ferroptosis-Related Signature is Closely Associated with the Prognosis and Tumor Immune Escape of Patients with Glioma. Int J Gen Med. 2022;15:253\u201370.","journal-title":"Int J Gen Med"},{"key":"2919_CR54","volume":"140","author":"C Yang","year":"2024","unstructured":"Yang C, Guo W, He R, Meng X, Fu J, Lu Y. Dietary capsaicin attenuates cardiac injury after myocardial infarction in type 2 diabetic mice by inhibiting ferroptosis through activation of TRPV1 and Nrf2\/HMOX1 pathway. Int Immunopharmacol. 2024;140:112852.","journal-title":"Int Immunopharmacol"},{"key":"2919_CR55","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.7150\/jca.95328","volume":"15","author":"Z Lin","year":"2024","unstructured":"Lin Z, Liu Z, Pan Z, Zhang Y, Yang X, Feng Y, et al. EGR1 Promotes Erastin-induced Ferroptosis Through Activating Nrf2-HMOX1 Signaling Pathway in Breast Cancer Cells. J Cancer. 2024;15:4577\u201390.","journal-title":"J Cancer"},{"key":"2919_CR56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jhep.2021.05.015","volume":"75","author":"R Kolamunnage-Dona","year":"2021","unstructured":"Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, et al. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol. 2021;75:879\u201387.","journal-title":"J Hepatol"},{"key":"2919_CR57","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39:3002\u201311.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2919_CR58","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N. Engl J Med. 2018;379:2417\u201328.","journal-title":"N. Engl J Med"},{"key":"2919_CR59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21:95\u2013104.","journal-title":"Lancet Oncol"},{"key":"2919_CR60","volume":"10","author":"S Li","year":"2023","unstructured":"Li S, Xu L, Wu G, Huang Z, Huang L, Zhang F, et al. Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib. Adv Sci (Weinh). 2023;10:e2207118.","journal-title":"Adv Sci (Weinh)"},{"key":"2919_CR61","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","volume":"38","author":"T Eisen","year":"2020","unstructured":"Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2020;38:4064\u201375.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2919_CR62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"2919_CR63","volume":"10","author":"Y He","year":"2023","unstructured":"He Y, Zhan L, Shi J, Xiao M, Zuo R, Wang C, et al. The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma. Adv Sci (Weinh). 2023;10:e2207650.","journal-title":"Adv Sci (Weinh)"},{"key":"2919_CR64","volume":"20","author":"XD Yang","year":"2021","unstructured":"Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, et al. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021;20:20.","journal-title":"Mol Cancer"},{"key":"2919_CR65","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2019-318506","volume":"69","author":"C Wang","year":"2020","unstructured":"Wang C, Wang H, Lieftink C, du Chatinier A, Gao D, Jin G, et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 2020;69:727\u201336.","journal-title":"Gut"},{"key":"2919_CR66","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","volume":"40","author":"JA Pollard","year":"2022","unstructured":"Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3\/ITD+ Acute Myeloid Leukemia: A Report From the Children\u2019s Oncology Group Protocol AAML1031. J Clin Oncol: Off J Am Soc Clin Oncol. 2022;40:2023\u201335.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"2919_CR67","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201\u201312.","journal-title":"Lancet Oncol"},{"key":"2919_CR68","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1078-0432.CCR-21-4450","volume":"28","author":"H Inaba","year":"2022","unstructured":"Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, et al. Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clin Cancer Res. 2022;28:2536\u201346.","journal-title":"Clin Cancer Res"},{"key":"2919_CR69","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2141.2012.09139.x","volume":"158","author":"A Guidetti","year":"2012","unstructured":"Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, et al. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol. 2012;158:108\u201319.","journal-title":"Br J Haematol"},{"key":"2919_CR70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-6-46","volume":"6","author":"DR Greenwald","year":"2013","unstructured":"Greenwald DR, Li H, Luger SM, Go RS, King D, Patel T, et al. A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). J Hematol Oncol. 2013;6:46.","journal-title":"J Hematol Oncol"},{"key":"2919_CR71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.12944","volume":"167","author":"JF Gibson","year":"2014","unstructured":"Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, et al. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. Br J Haematol. 2014;167:141\u20134.","journal-title":"Br J Haematol"},{"key":"2919_CR72","first-page":"146","volume":"28","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Wang X, An YH, Sun W, Tong XM. [Mechanism of Sorafenib and Decitabine Inducing Apoptosis of Diffuse Large B-Cell Lymphoma Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28:146\u201352.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2919_CR73","doi-asserted-by":"crossref","first-page":"45687","DOI":"10.18632\/oncotarget.17669","volume":"8","author":"MK Kiessling","year":"2017","unstructured":"Kiessling MK, Nicolay JP, Schlor T, Klemke CD, Suss D, Krammer PH, et al. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget. 2017;8:45687\u201397.","journal-title":"Oncotarget"},{"key":"2919_CR74","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1078-0432.CCR-12-1935","volume":"19","author":"S Xargay-Torrent","year":"2013","unstructured":"Xargay-Torrent S, Lopez-Guerra M, Montraveta A, Saborit-Villarroya I, Rosich L, Navarro A, et al. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. Clin Cancer Res. 2013;19:586\u201397.","journal-title":"Clin Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02919-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02919-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:15:04Z","timestamp":1739837704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02919-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,9]]}},"alternative-id":["2919"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02919-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethical Committee of Shandong Provincial Hospital (SZRJJ:NO.2022-123) and written informed consent in accordance with the Declaration of Helsinki was obtained from each patient. All animal experiments were approved by Animal Care and Research Advisory Committee of Shandong Provincial Hospital (NO.SD NSFC 2023-0185). All methods were performed in accordance with its relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}